These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29185855)

  • 1. Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells.
    Banisadr A; Safdari Y; Kianmehr A; Pourafshar M
    Hum Vaccin Immunother; 2018 Apr; 14(4):856-863. PubMed ID: 29185855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
    Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
    Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Evaluation of a Cetuximab-based Humanized Single Chain Antibody Against EGFR-overexpressing Tumors.
    Veisi K; Farajnia S; Zarghami N; Khorshid HR; Samadi N; Safdari Y; Ahmadzadeh V
    Drug Res (Stuttg); 2015 Dec; 65(12):624-8. PubMed ID: 25333654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW.
    Amini A; Safdari Y; Tash Shamsabadi F
    Mol Imaging; 2022; 2022():9589820. PubMed ID: 35517713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer.
    Fu W; Sun H; Zhao Y; Chen M; Yang L; Yang X; Jin W
    Mol Immunol; 2018 Jul; 99():124-133. PubMed ID: 29777999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.
    Kim YP; Park D; Kim JJ; Chi WJ; Lee SH; Lee SY; Kim S; Chung JM; Jeon J; Lee BD; Shin JH; Lee YI; Cho H; Lee JM; Kang HC
    PLoS One; 2014; 9(12):e113442. PubMed ID: 25438047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli.
    Akbari V; Sadeghi HM; Jafarian-Dehkordi A; Abedi D; Chou CP
    Protein Expr Purif; 2015 Dec; 116():66-74. PubMed ID: 26166178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.
    Khantasup K; Chantima W; Sangma C; Poomputsa K; Dharakul T
    Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):404-17. PubMed ID: 26683180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells
    Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
    Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
    Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
    Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer.
    Yu F; Wang Y; Xiao Y; He Y; Luo C; Duan D; Li C; Xu S; Xiang T
    Mol Immunol; 2014 May; 59(1):100-9. PubMed ID: 24534066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
    Ahmadzadeh V; Farajnia S; Hosseinpour Feizi MA; Khavarinejad RA
    Protein Expr Purif; 2014 Oct; 102():45-51. PubMed ID: 25088934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prokaryotic expression and refolding of EGFR extracellular domain and generation of phage display human scFv against EGFR.
    Zhou Y; Zhang J; Jin H; Chen Z; Wu Q; Li W; Yue M; Luo C; Wang M
    Biomed Pharmacother; 2013 Oct; 67(8):737-43. PubMed ID: 23639232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction and screening of phage antibody libraries against epidermal growth factor receptor and soluble expression of single chain Fv].
    Sheng WJ; Miao QF; Zhen YS
    Yao Xue Xue Bao; 2009 Jun; 44(6):597-602. PubMed ID: 19806889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A collagen-binding EGFR single-chain Fv antibody fragment for the targeted cancer therapy.
    Liang H; Li X; Chen B; Wang B; Zhao Y; Zhuang Y; Shen H; Zhang Z; Dai J
    J Control Release; 2015 Jul; 209():101-9. PubMed ID: 25916496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
    Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
    J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.
    Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK
    MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.